Generic Name Actual Dose, Classification Indication Mechanism of action Adverse Effects Nursing consideration

(Brand Name) Route,

Frequency,
Timing

 Monitor degree of
Fluticason Therapeutic:  Seasonal or  CNS: nasal stuffiness
Potent, locally acting anti-
(Avamys) 2 sprays per Anti- perennial allergic Headache ,amount and color of
inflammatory and immune
nasal discharge, and
nostril, OD , 8am inflammatory rhinitis. modifier.
 EENT:
frequency of
(steroidal) epistaxis, nasal
Therapeutic effects: sneezing.
Date ordered: burning, nasal
 Patients on long-
decrease in symptoms of
02 / 16 / 18 Pharmacologic: irritation,
allergic and nonallergic term therapy should
corticosteroids nasopharyngeal
rhinitis have periodic
fungal infection, otolaryngologic
pharyngitis. examinations to
 Gi: Nausea, monitor nasal
vomiting mucosa and
 Endo: Adrenal passages for

suppression infection or
ulceration.
 Derm: Rash,
 Monitor growth
uticaria
rate in children
 Resp: Cough
 Misc: receiving chronic
Anaphylaxis, therapy; use
Angioedema lowest possible
dose.
 Monitor for signs
and symptoms of
hypersensitivity
reactions (rash,
pruritis, swelling of
face and neck,
dyspnea)
periodically during
therapy.
  Assess patient
 CNS: depression, for symptoms of
 Reduction of Inhibits platelet
dizziness, fatigue, stroke ,peripheral
Clopidogrel 75 mg tab,OD Therapeutic: atherosclerotic aggregation by
headache. vascular disease,
(Plavix) PO, 1pm Antiplatelet events (MI, stroke, irreversibly inhibiting
 EENT: epistaxis. or MIperiodi- cally
agents vascular death) in the binding of ATP to
 Resp: cough, during therapy.
patients at risk for platelet receptors.
Date ordered: Pharmacologic: such events
dyspnea, eosinophilic  Monitor patient
Therapeutic
pneumo- nia. for signs of
02 / 16 / 18 Platelet including recent Effects: Decreased
 CV: chest pain, thrombotic
aggregation MI occurrence of
edema, hypertension. thrombocytic
inhibitors atherosclerotic
 GI: GI bleeding, purpura (throm-
events in patients at
abdominal pain, diar- bocytopenia,
risk.
rhea, dyspepsia, microangiopathic
gastritis. hemolytic
 Derm: Drug rash with anemia,
eosinophilia and neurologic
systemic symptoms, findings, renal
pruritus, purpura, dysfunction,
rash. fever). May rarely
occur, even after
 Hemat: Bleeding, short exposure
neutropenia, (􏰁2 wk).
thromboctic Requires prompt
thrombocytopenic treatment.
purpura  Lab Test
 Metab: Considerations:
hypercholesterolemia. Monitor bleeding
 MS: arthralgia, back time during
pain. therapy. Pro-
 Misc: fever, longed bleeding
hypersensitivity time, which is
reactions. time- and dose-
dependent, is
expected.
 Monitor CBC with
differential and
platelet count
periodically
during therapy.
Neutropenia and
thrombocytopenia
may rarely occur.
 May cause serum
bilirubin, hepatic
enzymes, total
cholesterol,
nonprotein ni-
trogen (NPN),
and uric acid
concentrations.
 Therapeutic:  Perioperative  Assess for infection
The bactericidal  CNS: Seizures (high
Ceftriaxone 2gm IVTT, OD, Antibiotic Prophylaxis (vital signs;
activity of ceftriaxone doses).
(Rocephin) 6am Anti-Infectives appearance of
results from inhibition  GI:
wound ,sputum
of bacterial cell wall Pseudomembranous
Pharmacologic: ,urine ,and stool;
synthesis. Colitis, diarrhea,
Date ordered: Cephalosporin WBC) at beginning
Ceftriaxone exerts in- cholelithia- sis,
02 / 16 / 18 of and throughout
vitro activity against a gallbladder sludging.
therapy.
wide range of gram-  Derm: rashes,
 Before initiating
negative and gram- urticaria.
therapy, obtain a
positive  Hemat: bleeding,
history to determine
microorganisms. eosinophilia,
previous use of and
Ceftriaxone is highly hemolytic anemia,
reactions to
stable to most ß- leukopenia,
penicillins or
lactamases, both thrombocytosis.
cephalosporins.
penicillinases and  Local: pain at IM
Persons with a
cephalosporinases, of site, phlebitis at IV
negative history of
gram-positive and site.
penicillin sensitivity
gram-negative  Misc: allergic
may still have an
bacteria. reactions including
allergic response.
Anaphylaxis,  Obtain specimens
superinfection for culture and
sensitivity before
initiating therapy.
First dose may be
given before
receiving results.
 Observe patient for
signs and symptoms
of anaphylaxis (rash,
pruritus, laryngeal
edema, wheezing).
Discontinue the drug
and notify health
care professional
immediately if these
symptoms occur.
Keep epinephrine,
an antihistamine,
and resuscitation
equipment close by
in the event of an
 anaphylactic
reaction.
 Monitor bowel
function. Diarrhea,
abdominal
cramping, fever, and
bloody stools should
be reported to health
care professional
promptly as a sign of
pseudomembranous
colitis. May begin up
to several weeks
following cessation
of therapy.
PRN MEDICATIONS

 Monitor respiratory
1 Neb ,PRN, Therapeutic: status and lung
Budesonide Now Anti-  Chronic Potent, locally acting  CNS:
sounds.
control of anti-inflammatory and headache.
(Bronex) inflammatory  Assess pulmonary
persistent immune modifier.  Derm: rash.
(steroidal) function tests
bronchial Therapeutic Effects:  EENT: otitis
periodically during
asthma Decreases media,
Date ordered: Pharmacologic: and for several
frequency/severity of dysphonia,
02 / 20 / 18 Corticosteroids months following a
asthma attacks. epistaxis,
transfer from
Improves asthma oropharyngeal
systemic to
symptoms. fungal
inhalation
infections,
corticosteroids.
pharyngitis,
 Assess patients
rhinitis,
changing from
sinusitis.
systemic
 Resp:
corticosteroids to
bronchospasm,
inhalation corticoste-
cough.
roids for signs of
 GI: abdominal
adrenal insufficiency
pain, diarrhea,
(anorexia, nausea,
 dyspepsia, weakness, fatigue,
gastroenteritis, hypotension,
nausea, hypoglycemia)
vomiting. during initial therapy
 Endo: adrenal and periods of
suppression stress. If these signs
(high dose, appear, notify health
long-term care professional
therapy only), immediately;
weight gain. condition may be
 MS: back pain. life- threatening.
Misc:  Monitor for
Anaphylaxis, withdrawal
flu-like symptoms (fatigue,
syndrome. weakness, nausea,
vomiting,
hypotension, joint or
muscular pain,
lassitude,
depression) during
withdrawal from oral
corticosteroids.